

TREATMENT UPDATE:

Diffuse Large B-Cell Lymphoma (DLBCL)

**CANCERCARE
CONNECT®
BOOKLET SERIES**



CANCER*care*®

WWW.CANCERCARE.ORG



CANCER*care*®

The CancerCare Connect® Booklet Series offers up-to-date, easy-to-read information on the latest treatments, managing side effects and coping with cancer.

For over 80 years, CancerCare has empowered millions of people affected by cancer through free counseling, resource navigation, support groups, educational resources, advocacy and direct financial assistance. Our oncology social workers improve the lives of people diagnosed with cancer, caregivers, survivors and the bereaved, by addressing their emotional, practical and financial challenges. To learn more, visit www.cancercares.org.

CancerCare relies on the generosity of supporters to provide our services completely free of charge to anyone facing a cancer diagnosis. If you have found this resource helpful and wish to donate, please do so online at www.cancercares.org/donate. You may also mail a check, payable to CancerCare, to CancerCare, Attn: Donations, 485 Madison Avenue, New York, NY 10022.

Thank you.

CancerCare®
National Office
485 Madison Avenue
New York, NY 10022

Toll-free 800-813-HOPE (4673)
Fax 212-712-8495
Email info@cancercares.org
Web www.cancercares.org

The content of this booklet is independent, non-promotional and free of commercial influence and bias.

Treatment Update: Diffuse Large B-Cell Lymphoma (DLBCL)

TABLE OF CONTENTS

Introduction.....	2
Diagnosis and Staging.....	3
Treatment Options.....	4
Treatment-Specific Side Effects.....	9
General Side Effects.....	13
Communicating With Your Health Care Team.....	17
CancerCare’s Free Support Services and Programs.....	19
Frequently Asked Questions.....	20
Resources.....	23

©2025 CancerCare®. All rights reserved. 05/2025

All people depicted in the photographs in this booklet are models, used for illustrative purposes only.

Diffuse large B-cell lymphoma (DLBCL) is a cancer that starts in white blood cells called lymphocytes. More than 18,000 people in the United States are diagnosed with DLBCL each year.

There are two types of lymphoma: Hodgkin's and non-Hodgkin's. DLBCL is the most common type of non-Hodgkin's lymphoma. In about 60 percent of cases, DLBCL grows in the lymph nodes, small bean-shaped organs located throughout the body that remove waste and fluids and help fight infection. DLBCL that develops in a place other than the lymph nodes is called "extranodal." The most common places where extranodal DLBCL develops are the stomach and gastrointestinal tract. There are two major subtypes of DLBCL: germinal center B-cell (GCB) and activated B-cell (ABC).



Diagnosis and Staging

The first sign of DLBCL is often a painless, quickly-growing mass (lump) in the neck, groin or abdomen. If DLBCL is suspected, a biopsy is performed, in which all or part of the mass is removed surgically and examined under a microscope. If a diagnosis of DLBCL is confirmed, further tests are performed to “stage” the cancer. Stages of DLBCL are defined as follows:

- **Stage I:** The cancer is in only one lymph node region, lymph structure or other site.
- **Stage II:** The cancer is in two or more lymph node regions or structures on one side of the diaphragm (the large muscle that separates the belly from the chest).
- **Stage III:** The cancer is in lymph node regions or structures on both sides of the diaphragm.
- **Stage IV:** The cancer has spread to other tissues and organs, which may include the liver, lungs or bone marrow.

As DLBCL can advance quickly, it usually requires immediate treatment once diagnosed.

Treatment Options

Chemotherapy-based approaches

The standard of care for newly-diagnosed DLBCL is a regimen called R-CHOP: rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone. Rituximab is a monoclonal antibody, a lab-generated protein that helps the immune system recognize and destroy cancer cells. Cyclophosphamide, doxorubicin and vincristine are chemotherapies. Prednisone is a steroid.

In stage III or IV DLBCL, the R-CHOP regimen is usually given once every 21 days over the course of 6-8 cycles. The drugs, except for the prednisone, are given as an infusion. The prednisone is given orally. Fewer cycles (3-4) may be used in the treatment of localized (stage I or II) DLBCL. Sometimes the chemotherapy etoposide (Etopophos, Vepesid) is added to the R-CHOP regimen. If this is the case, the regimen is called R-CHOEP.

A related regimen, R-EPOCH, is the use of the same drugs administered as a continuous infusion over the course of 4 days. The treatment is repeated every 21 days over the course of several cycles as determined by the person's individual circumstances.

Additionally, the monoclonal antibody rituximab/hyaluronidase human (Rituxan Hycela) can be given as an initial treatment for DLBCL, in combination with R-CHOP or R-CHOEP. It is given as a subcutaneous (beneath the skin) injection.

Radiation Therapy

In addition to chemotherapy-based regimens, “external beam” radiation therapy is typically used to treat localized DLBCL. This form of radiation therapy uses a machine outside of the body to generate a radiation beam. It is typically given five days per week for 3-4 weeks.

Car T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a person’s own T-cells (a type of white blood cell) to treat certain types of relapsed (recurred) or refractory (not responding to treatment) lymphomas, including DLBCL.

The CAR T-cell therapies approved by the U.S. Food and Drug Administration (FDA) for DLBCL are axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi) and tisagenlecleucel (Kymriah).

Based on a person’s specific situation, CAR T-cell therapy may be conducted on an outpatient basis or require a hospital admission. The process is similar regardless of the drug used or the specific subtype of DLBCL:

- Blood is drawn from the patient via an intravenous catheter (a flexible tube).
- T-cells are isolated from the rest of the blood.
- In a laboratory, the T-cells are genetically re-engineered by adding a chimeric antigen receptor to their surface.
- The modified T-cells (which are now CAR T-cells) are expanded to number in the hundreds of millions.
- The CAR T-cells are infused back into the patient where they target and destroy cancer cells.

Bispecific Antibodies

In May 2023, the FDA granted accelerated approval to epcoritamab (Epkiny) for relapsed or refractory DLBCL after treatment with two or more lines of systemic therapy. Epcoritamab-bysp is given as a subcutaneous (under the skin) injection.

In June 2023, the FDA granted accelerated approval to glofitamab (Columvi) for relapsed or refractory DLBCL after treatment with two or more lines of systemic therapy. Glofitamab-gxbm is given intravenously (through a needle or tube into a vein).

Both epcoritamab and glofitamab are bispecific antibodies, a type of immunotherapy that aims at two disease targets, increasing the treatment's potency against cancer.

Antibody-Drug Conjugate

An antibody drug conjugate (ADC) is formed by combining a monoclonal antibody (a lab-generated protein) to a chemotherapy. The antibody seeks out and hones in on a specific molecule on the tumor cell, bringing the chemotherapy with it. This approach can kill tumor cells or stop them from dividing while limiting the harm to normal cells.

- In April 2023, the FDA approved the combination of polatuzumab vedotin (Polivy) and R-CHOP as a treatment for patients with previously untreated DLBCL.
- In February 2025, the FDA approved the ADC brentuximab vedotin (Adcetris) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory DLBCL, not able to be treated with stem cell transplant or CAR T-cell therapy.

Note about stem cell transplant

Stem cell transplant has been an established treatment for DLBCL for several decades. However, it is used less frequently than in the past as newer options have become available, such as CAR T-cell therapy.



The Importance of Clinical Trials

Clinical trials are the standard by which we measure the worth of new treatments and the quality of life of patients as they receive those treatments. For this reason, doctors and researchers urge people with cancer to take part in clinical trials.

Your doctor can guide you in making a decision about whether a clinical trial is right for you. Here are a few things that you should know:

- Often, people who take part in clinical trials gain access to and benefit from new valuable treatments.
- Before you participate in a clinical trial, you will be fully informed as to the risks and benefits of the trial, including any possible side effects.
- Most clinical trials are designed to test a new treatment against a standard treatment to find out whether the new treatment has any added benefit.
- You can stop taking part in a clinical trial at any time for any reason.

Treatment-Specific Side Effects

All cancer treatments can cause side effects. It's important that you report any side effects that you experience to your health care team so they can help you manage them. Report them right away—don't wait for your next appointment. Doing so will improve your quality of life and allow you to stick with your treatment plan. It's important to remember that not all people experience all side effects, and people may experience side effects not listed here.

Chemotherapy-based approaches

- Hair loss
- Increased risk of infection (from having too few white blood cells)
- Anemia (low number of red blood cells)
- Easy bruising or bleeding
- Peripheral neuropathy (numbness or tingling in hands and feet)



Radiation Therapy

The side effects of radiation therapy can include dryness, swelling, peeling, redness and (rarely) blistering. If a reaction occurs, contact your health care team so the appropriate treatment can be prescribed. It's especially important to contact your health care team if there is any open skin or painful area, as this could indicate an infection. Infections can be treated with an oral antibiotic or topical antibiotic cream.


CAR T-Cell Therapy

Immunotherapy, including CAR T-cell therapy, travels through the bloodstream to help prompt what is called an "immune response." Because immunotherapy can affect healthy cells as well as cancer cells, certain side effects may be experienced. The potential side effects associated with CAR T-cell therapy include:

- **Cytokine-Release Syndrome (CRS).** The infusion of CAR T-cells into the body results in the production of large numbers of cytokines (molecules that help cells communicate), which can cause the immune system to become excessively active. This can lead to CRS, with symptoms such as high fever and flu-like symptoms. These side effects can be controlled and reversed with cytokine-blocking drugs and steroids.
- **Immune effector cell-associated neurotoxicity syndrome (ICANS).** This condition causes inflammation in the brain, affecting abilities such as speech, movement and thinking. Some people with ICANS can recover spontaneously. Anti-inflammatory medications, such as corticosteroids, can be prescribed for more severe cases.

- **B-Cell Aplasia.** The FDA-approved CAR T-cell therapies destroy normal as well as cancerous B-cells, which can cause B-cell aplasia (low numbers of B-cells), in which the body is less able to make the antibodies that protect against infection. Immunoglobulin replacement, administered intravenously, can be used to treat or prevent infection.
- **Tumor Lysis Syndrome (TLS).** When cancer cells break down (are destroyed) very quickly, they release large amounts of potassium, phosphate and uric acid into the blood. This can result in TLS, a group of conditions that can cause neurological, heart or kidney problems. TLS is managed by medicines that decrease potassium and uric acid levels in the blood. Medicines may also be prescribed that help increase urination.
- **Changes in cognition.** Some changes in cognition (thought processes) ranging from mild to severe can occur within several days of CAR T-cell therapy. The symptoms are often treated with steroids and are almost always reversible.

Because of these potential side effects, people who undergo CAR T-cell therapy should stay close to their treatment location for at least four weeks, so they can be closely monitored by their healthcare team.



Bispecific Antibodies

Among other side effects, treatment with bispecific antibodies is associated with CRS and ICANS (both described in the previous section) and increased risk of infection.

Antibody-Drug Conjugate

Side effects of ADCs include nausea, diarrhea, vomiting, constipation, fatigue, hair loss and peripheral neuropathy. The specific side effects can vary depending on the type of ADC and the person's overall health.



General Side Effects

Some side effects may occur across treatment approaches.

Following is guidance on how to manage these side effects should they occur.

Managing Digestive Tract Symptoms

Nausea and vomiting

- Avoid food with strong odors, as well as overly sweet, greasy, fried or highly seasoned food.
- Eat meals that are chilled, which often makes food more easily tolerated.
- Nibble on dry crackers or toast. These bland foods are easy on the stomach.
- Having something in your stomach when you take medication may help ease nausea.

Diarrhea

- Drink plenty of water. Ask your doctor about using drinks such as Gatorade, which provide electrolytes. Electrolytes are body salts that must stay in balance for cells to work properly.
- Over-the-counter medicines such as loperamide (Imodium A-D and others) and prescription drugs are available for diarrhea but should be used only if necessary and with your health care team's guidance. If the diarrhea is bad enough that you need medicine, contact a member of your health care team.

- The BRAT diet (bananas, rice, applesauce, toast) and soluble fiber such as oats, bran and barley can help with diarrhea. Foods high in insoluble fiber, such as leafy greens and most fruits should be avoided as they can worsen diarrhea. Oily foods, caffeine and alcohol should also be avoided.
- Avoid food high in refined sugar and those sweetened with sugar alcohols such as sorbitol and mannitol.

Constipation

- As hydration is important to avoid constipation, make sure to drink plenty of fluids. Also, limit your intake of caffeine and alcoholic beverages, as they can cause dehydration.
- Include foods high in fiber in your daily diet, such as fruit (especially pears and prunes), vegetables and cereals. If your health care team approves, you may want to add synthetic fiber to your diet, such as Metamucil, Citrucel or FiberCon.
- Be as physically active as you can, after checking with your health care team on the level of physical activity that is right for you.
- If your doctor has prescribed a “bowel regimen,” make sure to follow it exactly.



Managing loss of appetite

- Eating small meals throughout the day is an easy way to take in more protein and calories, which will help maintain your weight. Try to include protein in every meal.
- To keep from feeling full early, avoid liquids with meals or take only small sips (unless you need liquids to help swallow). Drink most of your liquids between meals.
- Keep high-calorie, high-protein snacks on hand such as hard-boiled eggs, peanut butter, cheese, ice cream, granola bars, liquid nutritional supplements, puddings, nuts, canned tuna or trail mix. If your doctor has prescribed a “bowel regimen,” make sure to follow it exactly.
- If you are struggling to maintain your appetite, talk to your health care team about whether appetite-building medication could be right for you.

Managing Fatigue

Fatigue (extreme tiredness not helped by sleep) is one of the most common side effects of many cancer treatments. If you are taking a medication, your doctor may lower the dose of the drug, as long as it does not make the treatment less effective. If you are experiencing fatigue, talk to your doctor about whether taking a smaller dose is right for you.

There are a number of other tips for reducing fatigue:

- To be able to sleep well at night, avoid excessive sleep during the day.
- Take short walks or do some light exercise, if possible.
- Try easier or shorter versions of the activities you enjoy.
- Ask your family or friends to help you with tasks you find difficult or tiring.

Fatigue can be a symptom of other illnesses, such as anemia, diabetes, heart disease, rheumatoid arthritis and depression. So be sure to ask your doctor if they think any of these conditions may be contributing to your fatigue.

Managing Pain

To help your doctor prescribe the best medication, it's useful to give an accurate report of your pain. Keep a journal that includes information on:

- When and where the pain occurs
- How long it lasts
- How strong it is on a scale of 1 to 10, with 1 being the least amount of pain and 10 the most intense
- What makes the pain feel better and what makes it feel more intense

There are a number of options for pain relief, including prescription and over-the-counter medications. It's important to talk to a member of your health care team before taking any over-the-counter medication, to determine if they are safe and will not interfere with your treatments. Physical therapy, acupuncture and massage may also be of help in managing your pain. Consult with a member of your health care team before beginning any of these activities.

Communicating With Your Health Care Team

As you manage your DLBCL, it's important to remember that you are a consumer of health care. The best way to make decisions about health care is to educate yourself about your diagnosis and get to know the members of your health care team, including doctors, nurse practitioners, physician assistants, nurses, dietitians, social workers and patient navigators.

Here are some tips for improving communication with your health care team:

Start a health care journal. Having a health care journal or notebook (either on paper or in a digital format) will allow you to keep all of your health information in one place. You may want to write down the names and contact information of the members of your health care team, as well as any questions for your doctor.

Prepare a list of questions. Before your next medical appointment, write down your questions and concerns. Because your doctor may have limited time, ask your most important questions first and be as specific as possible.

Bring someone with you to your appointments or have them be present during telehealth sessions. Even if you have a journal and a prepared list of questions or concerns, it's always helpful to have support when you go to your appointments. The person you bring may also think of questions to ask your doctor or remember details about your symptoms or treatment that you may have forgotten.

Write down your doctor's answers. Taking notes will help you remember your doctor's responses, advice and instructions. You can also ask the person who accompanies you to take notes for you, either in your journal or on a tablet or smartphone.

Record your visit if your doctor allows it. Recording the conversation with your doctor gives you a chance to hear specific information again or share it with family members or friends.

Incorporate other health care professionals into your team.

Your medical oncologist is an essential member of your health care team, but there are other health care professionals who can help you manage your diagnosis and treatment:

- Your primary care physician should be kept updated about your DLBCL treatment and any test results.
- Your local pharmacist is a great source of knowledge about the medications you are taking. Have all of your prescriptions filled at the same pharmacy to avoid the possibility of harmful drug interactions.
- Make sure your oncologist knows of any other medical conditions you have or any pain you are experiencing so that they can consult with your primary care physician or specialists as needed.

Remember, there is no such thing as over-communication.

CancerCare's Free Support Services and Programs

It can be very difficult to receive a diagnosis of DLBCL, and adjusting to the necessary changes in your life can be challenging.

CancerCare can help. We are a national nonprofit organization providing free, professional services to anyone affected by cancer. Our licensed oncology social workers can provide support and education, help in navigating the complicated health care system and offer information on support groups and other resources.

To learn more about how CancerCare helps, call us at 800-813-HOPE (4673) or visit www.cancercares.org.

You will likely also build your own personal support network composed of family and friends. In doing so, it's best to take some time to think about the people in your life and how they are best suited to help. Match the task to their strengths—ask a family member who loves to shop to pick up something for you at the store, or ask a friend who's a good listener to come over for a chat.



MORE ABOUT DLBCL

Frequently Asked Questions

Q: What treatment approaches for DLBCL are currently being studied?

A: There is a great deal of research being conducted for the treatment of DLBCL; for example:

- Results from a phase II clinical trial showed that the ABC subtype of relapsed or refractory DLBCL was more responsive to the targeted therapy ibrutinib (Imbruvica) than was the GCB subtype. This is important, as the ABC subtype is less likely to respond to standard R-CHOP treatment. Based on these results, an international phase III trial is underway comparing standard chemotherapy with or without ibrutinib in patients with non-GCB subtypes of DLBCL.
- Other research is exploring the addition of lenalidomide (Revlimid) to R-CHOP chemotherapy. The results to date seem to indicate show that this regimen may work better in the ABC subtype of DLBCL.

Q: Who is most likely to develop DLBCL?

A: Although DLBCL can develop in all age groups, it is most commonly found in middle-aged or older adults. Men are slightly more likely to develop DLBCL than women and it is more common in white people than in those of Asian or African descent. As DLBCL is not an inherited disease, family members of those with DLBCL are not at substantially increased risk of developing DLBCL.

Q: I have recently been diagnosed with DLBCL. What questions should I ask my oncologist about their recommended treatment approach?

A: Here are some questions you should ask; others will likely arise in the course of your discussions.

- What are the goals of treatment?
- How long will treatment last?
- Do you have any written information about this treatment?
- What medical procedures and expenses does my insurance plan cover?
- What are the side effects of this treatment?
- Are there any ways to help manage side effects?
- How do we know if a side effect is severe enough to call you?
- Are there any other treatment options?
- Are there any clinical trials we should be aware of?
- What is the best way to let you know when we have questions about treatment?



Q: What is a treatment summary and why is it important?

A: Keeping your own records up-to-date in the form of a treatment summary can be helpful, as it allows you and your family members to have instant access to the specifics of your DLBCL diagnosis and treatment. A treatment summary should include:

- Your name and date of birth
- Date of diagnosis
- Prescribed therapy/therapies, including dates started and stopped and dosages when appropriate
- Dates and types of baseline and post-diagnosis testing and the results of these tests
- Other medications and supplements you are taking
- Names, affiliations and contact information of all members of your health care team

Ask the members of your health care team what they suggest be included. Take your personal record with you when you visit any doctor, not just your oncologist.

Resources

CancerCare®

800-813-HOPE (800-813-4673)

www.cancercares.org

American Cancer Society

800-227-2345

www.cancer.org

National Cancer Institute

800-422-6237

www.cancer.gov

National Coalition for Cancer Survivorship

872-622-7937

www.canceradvocacy.org

Cancer Support Community

888-793-9355

www.cancersupportcommunity.org

Lymphoma Coalition

www.lymphomacoalition.org

Lymphoma Research Foundation

800-500-9976

www.lymphoma.org

Medicine Assistance Tool

medicineassistancetool.org

CLINICAL TRIAL WEBSITES**Clinicaltrials.gov**

www.clinicaltrials.gov

National Cancer Institute

www.cancer.gov

EmergingMed

www.emergingmed.com

This booklet was made possible by Novartis Oncology.



CANCER*care*[®]

Help and Hope

WWW.CANCERCARE.ORG
800-813-HOPE (4673)